Return on Equity (ROE): 20.19%
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 20.19% is 32% above its 5-year average of 15.31%, near the high end of its 5-year range (11.41%–20.46%).
As of Saturday, June 27, 2026. 7.42% above its 12-month average of 18.80%.
UHS Return on Equity (ROE) Chart
Annual fiscal-year return on equity; no daily interpolation.
UHS Average Return on Equity (ROE) Chart
UHS Current vs Average Return on Equity (ROE) Chart
UHS Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
20.19%
RETURN ON EQUITY (ROE) AVG TTM
18.80%
RETURN ON EQUITY (ROE) AVG 3Y
15.17%
RETURN ON EQUITY (ROE) AVG 5Y
15.31%
RETURN ON EQUITY (ROE) AVG 10Y
15.25%
RETURN ON EQUITY (ROE) AVG 15Y
15.68%
RETURN ON EQUITY (ROE) AVG 20Y
15.38%
CURRENT VS TTM AVG
+7.42%
CURRENT VS 3Y AVG
+33.11%
CURRENT VS 5Y AVG
+31.83%
CURRENT VS 10Y AVG
+32.40%
CURRENT VS 15Y AVG
+28.74%
CURRENT VS 20Y AVG
+31.24%
UHS Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Universal Health Services, Inc. (UHS) | $9.12B | 20.19% | 18.80% | 15.17% | 15.31% |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | 12.09% | 11.88% | 12.69% | 13.50% |
| Tempus AI, Inc. (TEM)vs › | $9.80B | -72.74% | -651.33% | -315.37% | -198.08% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.13B | 2.46% | -8.94% | -15.72% | 1.14% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -87.68% | -49.03% | -18.16% | -9.00% |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.39B | -6.28% | -2.13% | 6.32% | 9.65% |
| Oscar Health, Inc. (OSCR)vs › | $7.72B | -2.37% | -21.41% | -36.14% | -25.75% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.57B | -2.97% | 25.09% | 5.57% | 0.40% |
| Insulet Corp. (PODD)vs › | $10.96B | 23.25% | 25.41% | 19.99% | 14.02% |
| Bio-Techne Corporation (TECH)vs › | $11.12B | 5.25% | 5.98% | 10.62% | 11.34% |
Return Analysis
ROE
20.2%
ROA
9.7%
Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Universal Health Services, Inc. (UHS)?
- The return on equity (ROE) for UHS stock is 20.19%.
- Is Universal Health Services, Inc.'s return on equity (ROE) high or low?
- The return on equity (ROE) of 20.19% is 32% above its 5-year average of 15.31%, near the high end of its 5-year range (11.41%–20.46%).
- What is the TTM average return on equity (ROE) for Universal Health Services, Inc. (UHS)?
- The TTM average return on equity (ROE) for UHS stock is 18.80%.
- What is the 3Y average return on equity (ROE) for Universal Health Services, Inc. (UHS)?
- The 3Y average return on equity (ROE) for UHS stock is 15.17%.
- What is the 5Y average return on equity (ROE) for Universal Health Services, Inc. (UHS)?
- The 5Y average return on equity (ROE) for UHS stock is 15.31%.
- What is the 10Y average return on equity (ROE) for Universal Health Services, Inc. (UHS)?
- The 10Y average return on equity (ROE) for UHS stock is 15.25%.
- What is the 15Y average return on equity (ROE) for Universal Health Services, Inc. (UHS)?
- The 15Y average return on equity (ROE) for UHS stock is 15.68%.
- What is the 20Y average return on equity (ROE) for Universal Health Services, Inc. (UHS)?
- The 20Y average return on equity (ROE) for UHS stock is 15.38%.
UHS Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 20.46% |
| 2024-12-31 | 17.13% |
| 2023-12-31 | 11.67% |
| 2022-12-31 | 11.41% |
| 2021-12-31 | 16.28% |
| 2020-12-31 | 14.94% |
| 2019-12-31 | 14.80% |
| 2018-12-31 | 14.47% |
| 2017-12-31 | 15.08% |
| 2016-12-31 | 15.49% |
| 2015-12-31 | 16.01% |
| 2014-12-31 | 14.60% |
| 2013-12-31 | 15.71% |
| 2012-12-31 | 16.34% |
| 2011-12-31 | 17.34% |
| 2010-12-31 | 11.63% |
| 2009-12-31 | 14.87% |
| 2008-12-31 | 12.91% |
| 2007-12-31 | 11.23% |
| 2006-12-31 | 18.50% |
| 2005-12-31 | 19.99% |
| 2004-12-31 | 13.89% |
| 2003-12-31 | 18.27% |
| 2002-12-31 | 19.11% |
| 2001-12-31 | 12.35% |
| 2000-12-31 | 13.03% |
| 1999-12-31 | 12.13% |
| 1998-12-31 | 12.70% |
| 1997-12-31 | 12.78% |
| 1996-12-31 | 11.19% |
Related Metrics
About Universal Health Services, Inc.
Universal Health Services, Inc. (UHS), operating through its various divisions, is a healthcare entity that both owns and manages a network of acute care hospitals, along with outpatient and specialized behavioral health treatment centers. Its business operations are strategically bifurcated into two main segments: Acute Care Hospital Services and Behavioral Health Care Services. The hospitals under its management provide a comprehensive spectrum of medical provisions, encompassing general and specialty surgical interventions, internal medicine, obstetrics, urgent and emergency department services, diagnostic imaging (radiology), cancer therapy (oncology), advanced diagnostic procedures, cardiac care, pediatric medicine, pharmaceutical services, and mental health support. As of a reported date of February 24, 2022, the company's significant presence included the ownership or operation of 363 inpatient facilities, complemented by 40 outpatient and other specialized sites. These facilities are distributed across 39 U.S. states, the District of Columbia, the United Kingdom, and Puerto Rico. Beyond direct patient care, UHS also extends into commercial health insurance provision and offers a variety of crucial management support functions. These include centralized procurement, information technology infrastructure, financial oversight and control mechanisms, strategic facilities planning, physician talent acquisition, administrative staff management, marketing initiatives, and public relations efforts. Universal Health Services, Inc. was established in 1978 and maintains its principal executive offices in King of Prussia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Marc D. Miller